Manhattan Associates Inc vs Twist Bioscience Corp — how do they compare? Manhattan Associates Inc trades at $206.18 (market cap $12.06B), while Twist Bioscience Corp trades at $154.2 (market cap $10.08B). The key difference: Manhattan Associates Inc is the larger of the two by market cap, and Manhattan Associates Inc is trading nearer its 52-week high, Twist Bioscience Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Manhattan Associates Inc for 12 Days and Twist Bioscience Corp for 27 Days on average.
| MANH | TWST | |
|---|---|---|
Market Cap | $12.06B | $10.08B |
Volume | 376,150 | 4,229,037 |
Sector | Technology | Health |
52-Week High | $223.76 | $205.00 |
52-Week Low | $120.88 | $25.45 |
Typical Hold Time | 12 Days | 27 Days |
Enterprise Value | $11.93B | $10.01B |
Signals from Pluang's Aura AI — not financial advice
Manhattan Associates (MANH) trades at $202.11, down 0.36% with bearish technical signals but strong fundamentals. The stock shows robust profitability with 18.67% net margins and consistent earnings beats, though valuation multiples appear elevated. Recent news includes a law firm investigation into fiduciary duties and a downgrade to neutral by DA Davidson, while the company launched new solution editions to expand market reach.
The outlook balances strong operational performance against high valuation and legal scrutiny. Upside potential exists from continued earnings momentum and product innovation, but risks include the ongoing investigation and competitive pressures. Analyst consensus remains bullish with a $210.50 price target, suggesting modest upside from current levels.
TWST trades at $155.65, down 6.78% today, reflecting a bearish technical signal and recent earnings misses. Revenue growth is strong, rising to $376.57M in 2025, but profitability remains elusive with a net income margin of -31.66%. The company's partnership with Lilly TuneLab for AI-driven drug discovery has generated positive news flow, yet cash flow remains negative, and the stock trades at elevated valuation multiples like P/S of 22.01.
The outlook is mixed: strong analyst buy-side consensus (73% Buy) and strategic AI partnerships offer growth potential, but persistent losses, high cash burn, and bearish technicals pose significant risks. Investors face a trade-off between long-term innovation prospects and near-term financial instability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.
Read more on MANH →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →